Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03960554
Other study ID # AAAS3103
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date January 16, 2020
Est. completion date December 2, 2021

Study information

Verified date April 2022
Source Columbia University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase 2 Multi-Center Clinical Trial (safety and effectiveness trial) in 60 patients (40 denosumab; 20 placebo) who have had a kidney transplant for 12-months or longer with more than 30% of kidney function. The investigators will test whether denosumab safely improves bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA) and improves bone strength by high resolution peripheral quantitative computed tomography (HR-pQCT) in the subset of patients recruited at Columbia University Irving Medical Center. These data will inform the development and execution of a larger trial to test if denosumab prevents fractures in kidney transplant recipients.


Description:

Bone fractures are 3-times more common in kidney transplant recipients than in the general population and risk of dying after a hip fracture is 60% higher compared to kidney transplant recipients without a fracture. Unfortunately, there are no anti-fracture strategies that have been proven to be effective in double blinded randomized clinical trials for kidney transplant recipients. This is because some anti-fracture medications that are commonly used to treat osteoporosis and prevent fractures in the general population (i.e., bisphosphonates), may be harmful to the skeleton when kidney function is less than 30% of normal. In addition, intravenous bisphosphonates may be toxic to the kidneys, which further limits their utility in patients with a kidney transplant. Denosumab, a monoclonal antibody against RANKL, inhibits osteoclast function and is not harmful to the kidney. Denosumab prevents fractures in men and women with age-related and glucocorticoid-induced osteoporosis. Recently, a non-blinded randomized trial of denosumab versus usual care during the first year of kidney transplantation in 90 patients reported the bone mineral density (BMD) measured by dual energy X-ray absorptiometry (DXA) increased at the spine and hip and that bone strength measured by high resolution peripheral quantitative computed tomography (HR-pQCT) increased in patients treated with denosumab. Adverse events in denosumab-treated patients included greater risk of urinary tract infections, diarrhea, and transient levels of low serum calcium that were asymptomatic. This study demonstrated that denosumab safely increased BMD at the spine and hip in new kidney transplant recipients. However, long-term kidney recipients, who comprise the vast majority of patients living with a transplanted kidney and who are also at increased risk of fracture, were not included.


Recruitment information / eligibility

Status Terminated
Enrollment 15
Est. completion date December 2, 2021
Est. primary completion date December 2, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria 1. Men and women 2. All race-ethnicities 3. Age = 18 years 4. = 12-months after kidney transplantation (living or deceased donor recipient) 5. Stable allograft function over the previous year defined as: 1. No rejections 2. No more than a 15% decline in Glomerular filtration rate (GFR) over the prior year 6. Allograft GFR = 30 mL/minute/1.73 m2 (MDRD or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) per local lab reporting) 7. 25OHD = 30 ng/mL (determined at screening visit) 8. Serum calcium = 9.0 mg/dL (determined at screening visit) 9. T-Score at the spine including and between -1.0 and -3.5 (determined at screening visit) 10. Must have had a routine dental exam within 6-months of study recruitment 11. Must agree to continue with routine dental exams over the course of the study 12. Has not undergone an invasive dental procedure (i.e., tooth extraction, dental implants, oral surgery) within = 3-months of recruitment 13. Must agree to referral to metabolic bone disease specialist at the end of the study 14. Women of child bearing potential must be willing to use one form of effective contraception over the course of the study Exclusion Criteria 1. Allograft GFR < 30 mL/minute/1.73 m2 (MDRD or CKD-EPI per local lab reporting) 2. Within 24-months of starting renal replacement therapy 3. Prevalent or occult vertebral fractures 4. History of post-transplantation non-basal cell carcinoma cancers 5. Non-ambulatory 6. Malignancy requiring chemotherapy or metastatic to bone 7. Non-transplant related metabolic bone diseases that alter bone mineral density, including but not limited to Primary hyperparathyroidism, Paget's, Osteogenesis Imperfecta 8. Within one-year of parathyroidectomy 9. Untreated hyperthyroidism for 6-months or longer 10. Untreated hypothyroidism for 6-months of longer 11. Medical diseases (end stage liver, lung or heart, intestinal malabsorption) 12. Use within the prior year of bisphosphonates, teriparatide, selective estrogen receptor modulators, testosterone, estrogen, denosumab, abaloparatide, calcitonin, and romosozumab 13. Allergy to components within the denosumab preparation or to denosumab 14. Weight > 300 pounds 15. Parathyroid hormone (PTH) > 450 pg /mL 16. Will undergo an invasive dental procedure (i.e., tooth extraction, dental implants, oral surgery) within the next 12-months 17. Pregnant 18. Planned pregnancy during the course of the study

Study Design


Intervention

Drug:
Denosumab Inj 60 mg/ml
Treatment will be administered by study personnel as a subcutaneous injection every 6-months for one year.
Other:
Placebo
Placebo will be administered by study personnel as a subcutaneous injection every 6-months for one year.

Locations

Country Name City State
United States Northwestern University, Feinburg School of Medicine Chicago Illinois
United States NorthShore University HealthSystem Evanston Illinois
United States Columbia University Medical Center New York New York

Sponsors (1)

Lead Sponsor Collaborator
Thomas Nickolas, MD MS

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Bone mineral density (BMD) measured by dual energy X-ray absorptiometry (DXA) BMD will be measured to determine if 1-year of treatment with denosumab changes BMD as measured by DXA. 12 months
Primary Estimated bone strength measured by high resolution peripheral quantitative computed tomography (HR-pQCT) Imaging Estimated bone mechanical competence will be measured by HR-pQCT. 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06287502 - Efficacy of Structured Exercise-Nutritional Intervention on Sarcopenia in Patients With Osteoporosis N/A
Completed NCT03822078 - Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women Phase 1
Recruiting NCT05845021 - Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty N/A
Completed NCT00092066 - A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227) Phase 3
Recruiting NCT04754711 - Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition N/A
Completed NCT04736693 - Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data
Not yet recruiting NCT06431867 - Primary Care Management of Osteoporosis in Older Women
Completed NCT02922478 - Role of Comorbidities in Chronic Heart Failure Study
Recruiting NCT02635022 - Fragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study
Recruiting NCT02616627 - Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
Active, not recruiting NCT02617303 - Prevention of Falls and Its Consequences in Elderly People N/A
Completed NCT02566655 - Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis Phase 1
Completed NCT03420716 - Symbiotic Yogurt, Calcium Absorption and Bone Health in Young Adult Women N/A
Completed NCT02559648 - Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis Phase 2
Not yet recruiting NCT02223572 - Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture N/A
Not yet recruiting NCT01854086 - Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday N/A
Completed NCT02003716 - DeFRA Questionnaire as an Anamnestic Form N/A
Unknown status NCT01913834 - Nasally and sc Administered Teriparatide in Healthy Volunteers Phase 1
Completed NCT01757340 - Calorie Restriction With Leucine Supplementation N/A
Completed NCT01401556 - C-STOP Fracture Trial N/A